Baker Bros. Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Baker Bros. Advisors’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-223,976	Closed	-$8.51M	–	116
2022 Q4	$8.51M	Hold	223,976	–	–	0.05%	63
2022 Q3	$5.63M	Hold	223,976	–	–	0.04%	74
2022 Q2	$6.81M	Hold	223,976	–	–	0.04%	71
2022 Q1	$7.34M	Hold	223,976	–	–	0.04%	75
2021 Q4	$5.91M	Hold	223,976	–	–	0.03%	90
2021 Q3	$22.5M	Hold	223,976	–	–	0.1%	59
2021 Q2	$31.7M	Hold	223,976	–	–	0.14%	53
2021 Q1	$22.3M	Hold	223,976	–	–	0.1%	60
2020 Q4	$27.7M	Buy	223,976 +170,793	+321%	+$22.4M	0.1%	49
2020 Q3	$5.18M	Sell	53,183 -2,800	-5%	-$350K	0.02%	80
2020 Q2	$8.73M	Hold	55,983	–	–	0.04%	66
2020 Q1	$8.08M	Buy	55,983 +15,000	+37%	+$2.9M	0.05%	53
2019 Q4	$8.38M	Buy	+40,983	New	+$7.48M	0.04%	56

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baker Bros. Advisors's RETA Position: Q1 2023 in Review

Baker Bros. Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2023, closing a stake of 223,976 shares — an estimated $8.51M sold.

Baker Bros. Advisors first reported a position in RETA in Q4 2019 and held it in 13 quarters. The position peaked at $31.7M in Q2 2021. 205 funds tracked by Wall St. Rank hold RETA as of Q1 2023.

Baker Bros. Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2023 after selling out during the quarter.
Baker Bros. Advisors sold 223,976 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2023, an estimated $8.51M.
Baker Bros. Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2019 and held it in 13 quarters.
Baker Bros. Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $31.7M in Q2 2021.
205 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2023.

Based on Baker Bros. Advisors's 13F filing for Q1 2023, filed 15 May 2023.